NCT03631043View on ClinicalTrials.gov

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 21, 2018

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Smoldering Plasma Cell Myeloma
Interventions
PROCEDURE

Biopsy Specimen Radiography

Undergo collection of blood and bone marrow

DRUG

Lenalidomide

Given PO

BIOLOGICAL

Vaccine Therapy

Given personalized vaccine SC

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER